Page 23 - TD-2-1

Tumor Discovery Cancer progression in PCOS

J Pediatr, 102(3): 461–464. Definition, aetiology, diagnosis and treatment. Nat Rev
Endocrinol, 14(5): 270–284.
https://doi.org/10.1016/S0022-3476(83)80678-7
https://doi.org/10.1038/nrendo.2018.24
47. Van Hooff MH, Voorhorst FJ, Kaptein MB, et al., 2000,
Polycystic ovaries in adolescents and the relationship with 58. Azziz R, Carmina E, Chen Z, et al., 2016, Polycystic ovary
menstrual cycle patterns, luteinizing hormone, androgens, syndrome. Nat Rev Dis Primers, 2(1): 16057.
and insulin. Fertil Steril, 74(1): 49–58.
https://doi.org/10.1038/nrdp.2016.57
https://doi.org/10.1016/S0015-0282(00)00584-7
59. Lizneva D, Suturina L, Walker W, et al., 2016, Criteria,
48. Diamanti-Kandarakis E, Dunaif A, 2012, Insulin resistance prevalence, and phenotypes of polycystic ovary syndrome.
and the polycystic ovary syndrome revisited: An update on Fertil Steril, 106(1): 6–15.
mechanisms and implications. Endocr Rev, 33(6): 981–1030.
https://doi.org/10.1016/j.fertnstert.2016.05.003
https://doi.org/10.1210/er.2011-1034
60. Meczekalski B, Pérez-Roncero GR, López-Baena MT, et al.,
49. Zuo T, Zhu M, Xu W, 2016, Roles of oxidative stress in 2020, The polycystic ovary syndrome and gynecological
polycystic ovary syndrome and cancers. Oxid Med Cell cancer risk. J Gynaecol Endocrinol, 36(4): 289–293.
Longev, 2016: 8589318.
https://doi.org/10.1080/09513590.2020.1730794
https://doi.org/10.1155/2016/8589318
61. Barry JA, Azizia MM, Hardiman PJ, 2014, Risk of
50. Sabuncu T, Vural H, Harma M, et al., 2001, Oxidative stress endometrial, ovarian and breast cancer in women with
in polycystic ovary syndrome and its contribution to the risk polycystic ovary syndrome: A systematic review and meta-
of cardiovascular disease. Clin Biochem, 34(5): 407–413. analysis. Hum Reprod Update, 20(5): 748–758.
https://doi.org/10.1016/S0009-9120(01)00245-4 https://doi.org/10.1093/humupd/dmu012
51. Patel S, 2018, Polycystic ovary syndrome (PCOS), an 62. de França Neto AH, Rogatto S, Do Amorim MM, et al., 2010,
inflammatory, systemic, lifestyle endocrinopathy. J Steroid Oncological repercussions of polycystic ovary syndrome.
Biochem Mol Biol, 182: 27–36. J Gynaecol Endocrinol, 26(10): 708–711.
https://doi.org/10.1016/j.jsbmb.2018.04.008 https://doi.org/10.3109/09513590.2010.490607
52. Xue Z, Li J, Feng J, et al., 2021, Research progress on the 63. Parker SL, 1997, Cancer statistics, 1997. CA Cancer J Clin,
mechanism between polycystic ovary syndrome and 47: 5–27.
abnormal endometrium. Front Physiol, 12: 788772.
https://doi.org/10.3322/canjclin.47.1.5
https://doi.org/10.3389/fphys.2021.788772
64. National Cancer Institute of Canada, 2003, Canadian Cancer
53. Yang Y, Qiao J, Li R, et al., 2011, Is interleukin-18 associated Statistics. Toronto, Canada: National Cancer Institute.
with polycystic ovary syndrome? Reprod Biol Endocrinol, 65. Daniilidis A, Dinas K, 2009, Long term health consequences
9(1): 7.
of polycystic ovarian syndrome: A review analysis.
https://doi.org/0.1186/1477-7827-9-7 Hippokratia, 13(2): 90–92.
54. González F, Nair KS, Daniels JK, et al., 2012, 66. Hardiman P, Pillay OS, Atiomo W, 2003, Polycystic
Hyperandrogenism sensitizes leukocytes to hyperglycemia ovary syndrome and endometrial carcinoma. Lancet,
to promote oxidative stress in lean reproductive-age women. 361(9371): 1810–1812.
J Clin Endocrinol Metab, 97(8): 2836–2843.
https://doi.org/10.1016/S0140-6736(03)13409-5
https://doi.org/10.1210/jc.2012-1259
67. Pillay OC, Te Fong, LW, Crow JC, et al., 2006, The association
55. Rosenfield RL, Ehrmann DA, 2016, The pathogenesis of between polycystic ovaries and endometrial cancer. Hum
polycystic ovary syndrome (PCOS): The hypothesis of Reprod, 21(4): 924–929.
PCOS as functional ovarian hyperandrogenism revisited. https://doi.org/10.1093/humrep/dei420
Endocr Rev, 37(5): 467–520.
68. Atiomo W, Khalid S, Parameshweran S, et al., 2009,
https://doi.org/10.1210/er.2015-1104
Proteomic biomarkers for the diagnosis and risk stratification
56. Day F, Karaderi T, Jones MR, et al., 2018, Large-scale of polycystic ovary syndrome: A systematic review. BJOG,
genome-wide meta-analysis of polycystic ovary syndrome 116(2): 137–143.
suggests shared genetic architecture for different diagnosis https://doi.org/10.1111/j.1471-0528.2008.02041.x
criteria. PLoS Genet, 14(12): e1007813.
69. Gottschau M, Kjaer SK, Jensen A, et al., 2015, Risk of cancer
https://doi.org/10.1371/journal.pgen.1007813
among women with polycystic ovary syndrome: A Danish
57. Escobar-Morreale HF, 2018, Polycystic ovary syndrome: cohort study. Gynecol Oncol, 136(1): 99–103.

Volume 2 Issue 1 (2023) 10 https://doi.org/10.36922/td.328